Radka L. O.
- Country
- Czechia
- Department
- Dptm of Clinical Oncology
Research Overview
- Evaluation of EP102 for Safety and Efficacy in Patients with Advanced Solid Tumors
- Evaluation of a Novel Oral Anti-Tumor Agent in Patients with Metastatic or Locally Advanced Solid Tumors Lacking Standard Therapeutic Options
- Phase 3 Study of Subcutaneous vs. Intravenous Tislelizumab Plus Chemotherapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Data & Insights
Has run more than one trial at 2 of 27 partner sites.
Specializations
Breast cancer and gynecologic oncology
Clinical research in advanced breast cancer, metastatic triple-negative breast cancer, hormone receptor-positive and HER2-negative breast cancer, as well as HER2-positive breast cancer with high-risk recurrence features. Therapeutic interests also extend to ovarian cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and endometrial cancer.
- Advanced breast cancer
- Triple-negative breast cancer
- Ovarian and fallopian tube malignancies
- Endometrial cancer
Work in this area includes endocrine therapy, HER2-directed treatment, and antibody-drug conjugate strategies for breast and gynecologic tumors.
Genitourinary cancers
Strong involvement in renal cell carcinoma, including clear cell renal cell carcinoma, metastatic renal cell carcinoma, and advanced or relapsed renal tumors, alongside prostate cancer across metastatic castration-resistant, metastatic hormone-sensitive, and biochemically recurrent settings. Additional interest includes urothelial cancer and bladder carcinoma.
- Renal cell carcinoma
- Prostate cancer
- Urothelial and bladder cancer
- Clear cell renal tumors
Therapeutic focus includes immune checkpoint inhibition, targeted therapy, and hormonal treatment across advanced genitourinary malignancies.
Lung cancer and thoracic malignancies
Clinical trial activity covers non-small cell lung cancer, small cell lung cancer, stage III lung cancer, and molecularly defined subsets such as EGFR-mutated, RET fusion-positive, HER2-mutated, and c-MET overexpressing disease. Interest also includes esophageal cancer and gastroesophageal junction adenocarcinoma within the broader thoracic oncology field.
- Non-small cell lung cancer
- Small cell lung cancer
- Esophageal and gastroesophageal junction cancer
- Molecularly selected thoracic tumors
The therapeutic emphasis is on immunotherapy, targeted agents, and combined modality approaches for advanced thoracic disease.
Gastrointestinal cancers and hepatobiliary oncology
Research participation includes colorectal cancer, gastric adenocarcinoma, gastroesophageal junction cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, and biliary tract cancer, with additional activity in gastrointestinal stromal tumor and neuroendocrine carcinoma. Molecularly selected disease groups such as KRAS G12C-mutated colorectal cancer and FGFR2b-overexpressing gastric cancer are also represented.
- Colorectal cancer
- Gastric and gastroesophageal junction cancer
- Pancreatic cancer
- Hepatobiliary malignancies
Therapeutic interests center on precision oncology, immune-based treatment, and targeted therapy for advanced gastrointestinal tumors.
Melanoma, sarcoma, and other advanced solid tumors
Additional clinical involvement includes advanced melanoma, glioblastoma, dedifferentiated liposarcoma, leiomyosarcoma, gastrointestinal stromal tumor, and broad cohorts of advanced solid tumors. The portfolio also extends to metastatic urothelial cancer, astrocytoma, and other unresectable or metastatic malignancies.
- Melanoma
- Sarcoma
- Glioblastoma
- Advanced solid tumors
Therapeutic domains include immuno-oncology, novel targeted agents, and treatment strategies for difficult-to-treat advanced cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.